230 related articles for article (PubMed ID: 30919442)
1. Causes of mortality and severe morbidity requiring euthanasia in captive Tasmanian devils (Sarcophilus harrisii) in Tasmania.
Peck SJ; Michael SA; Knowles G; Davis A; Pemberton D
Aust Vet J; 2019 Apr; 97(4):89-92. PubMed ID: 30919442
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of Cryptosporidium and Giardia from the Tasmanian devil (Sarcophilus harrisii).
Wait LF; Fox S; Peck S; Power ML
PLoS One; 2017; 12(4):e0174994. PubMed ID: 28423030
[TBL] [Abstract][Full Text] [Related]
3. High blood lead concentrations in captive Tasmanian devils (Sarcophilus harrisii): a threat to the conservation of the species?
Hivert LG; Clarke JR; Peck SJ; Lawrence C; Brown WE; Huxtable SJ; Schaap D; Pemberton D; Grueber CE
Aust Vet J; 2018 Nov; 96(11):442-449. PubMed ID: 30370598
[TBL] [Abstract][Full Text] [Related]
4. Salmonella in captive and wild Tasmanian devils (Sarcophilus harrisii) in Tasmania.
Michael SA; Harlock M; Peck SJ; Lazenby B; Pemberton D
Aust Vet J; 2020 Jun; 98(6):239-242. PubMed ID: 32090318
[TBL] [Abstract][Full Text] [Related]
5. Leptospirosis in Tasmanian Devils ( Sarcophilus harrisii ) in Tasmania, 2008-12.
Wynwood SJ; Burns MA; Graham GC; Weier SL; McKay DB; Peck S; Craig SB
J Wildl Dis; 2016 Jul; 52(3):636-41. PubMed ID: 27243149
[TBL] [Abstract][Full Text] [Related]
6. Season, weight, and age, but not transmissible cancer, affect tick loads in the endangered Tasmanian devil.
Belkhir S; Hamede R; Thomas F; Ujvari B; Dujon AM
Infect Genet Evol; 2022 Mar; 98():105221. PubMed ID: 35065301
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.
Pye R; Hamede R; Siddle HV; Caldwell A; Knowles GW; Swift K; Kreiss A; Jones ME; Lyons AB; Woods GM
Biol Lett; 2016 Oct; 12(10):. PubMed ID: 28120799
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous T-cell lymphoma in two captive Tasmanian devils (Sarcophilus harrisii).
Scheelings TF; Dobson EC; Hooper C
J Zoo Wildl Med; 2014 Jun; 45(2):367-71. PubMed ID: 25000700
[TBL] [Abstract][Full Text] [Related]
9. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.
Kreiss A; Brown GK; Tovar C; Lyons AB; Woods GM
Vaccine; 2015 Jun; 33(26):3016-25. PubMed ID: 25708088
[TBL] [Abstract][Full Text] [Related]
10. Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii).
Patchett AL; Flies AS; Lyons AB; Woods GM
Cell Mol Life Sci; 2020 Jul; 77(13):2507-2525. PubMed ID: 31900624
[TBL] [Abstract][Full Text] [Related]
11. HEMATOLOGICAL AND SERUM BIOCHEMICAL VALUES IN ANESTHETIZED CAPTIVE TASMANIAN DEVILS (SARCOPHILUS HARRISII).
Hope KL; Peck S
J Zoo Wildl Med; 2016 Jun; 47(2):564-72. PubMed ID: 27468030
[TBL] [Abstract][Full Text] [Related]
12. Hematologic and serum biochemical changes associated with Devil Facial Tumor Disease in Tasmanian Devils.
Peck S; Corkrey R; Hamede R; Jones M; Canfield P
Vet Clin Pathol; 2016 Sep; 45(3):417-29. PubMed ID: 27589840
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and carboplatin trials in Tasmanian devils (Sarcophilus harrisii) with Tasmanian devil facial tumor disease.
Phalen DN; Frimberger AE; Peck S; Pyecroft S; Harmsen C; Lola S; Moore AS
Vet J; 2015 Dec; 206(3):312-6. PubMed ID: 26538144
[TBL] [Abstract][Full Text] [Related]
14. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).
Hayes DA; Kunde DA; Taylor RL; Pyecroft SB; Sohal SS; Snow ET
PLoS One; 2017; 12(6):e0177919. PubMed ID: 28591206
[TBL] [Abstract][Full Text] [Related]
15. Isotopic niche variation in Tasmanian devils
Bell O; Jones ME; Cunningham CX; Ruiz-Aravena M; Hamilton DG; Comte S; Hamede RK; Bearhop S; McDonald RA
Ecol Evol; 2021 Jun; 11(12):8038-8053. PubMed ID: 34188870
[TBL] [Abstract][Full Text] [Related]
16. A second transmissible cancer in Tasmanian devils.
Pye RJ; Pemberton D; Tovar C; Tubio JM; Dun KA; Fox S; Darby J; Hayes D; Knowles GW; Kreiss A; Siddle HV; Swift K; Lyons AB; Murchison EP; Woods GM
Proc Natl Acad Sci U S A; 2016 Jan; 113(2):374-9. PubMed ID: 26711993
[TBL] [Abstract][Full Text] [Related]
17. Development of a SNP-based assay for measuring genetic diversity in the Tasmanian devil insurance population.
Wright B; Morris K; Grueber CE; Willet CE; Gooley R; Hogg CJ; O'Meally D; Hamede R; Jones M; Wade C; Belov K
BMC Genomics; 2015 Oct; 16():791. PubMed ID: 26467759
[TBL] [Abstract][Full Text] [Related]
18. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity.
Kreiss A; Cheng Y; Kimble F; Wells B; Donovan S; Belov K; Woods GM
PLoS One; 2011; 6(7):e22402. PubMed ID: 21811598
[TBL] [Abstract][Full Text] [Related]
19. Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population.
Pearse AM; Swift K; Hodson P; Hua B; McCallum H; Pyecroft S; Taylor R; Eldridge MD; Belov K
Cancer Genet; 2012 Mar; 205(3):101-12. PubMed ID: 22469509
[TBL] [Abstract][Full Text] [Related]
20. Seasonality and breeding success of captive and wild Tasmanian devils (Sarcophilus harrisii).
Keeley T; Russell T; Carmody K; Kirk G; Eastley T; Britt-Lewis A; Post M; Burridge M; Eccleston S; Faulkner T; Forge T; Leonard J; Hughes RL
Theriogenology; 2017 Jun; 95():33-41. PubMed ID: 28460677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
